1887

Chapter 40 : Analyzing Ethical Dilemmas in Gene Therapy

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Analyzing Ethical Dilemmas in Gene Therapy, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817480/9781555814724_Chap40-1.gif /docserver/preview/fulltext/10.1128/9781555817480/9781555814724_Chap40-2.gif

Abstract:

In the first approved human gene therapy experiment, W. French Anderson attempted to use genes to treat the genetic disease called severe combined immunodeficiency disease. The need for a standard review procedure for proposed human gene therapy experiments was made clear by an incident in 1979-1980, when a University of California-Los Angeles researcher tried a human gene therapy experiment on two patients without getting approval from the appropriate review committee at his institution. Leroy Walters, of Georgetown University's Kennedy Institute of Bioethics, divided gene therapy into four possible categories. The categories are somatic-cell gene therapy for the cure or prevention of disease, germ line gene therapy for the cure or prevention of disease, somatic-cell enhancement, and germ line enhancement. One of the ongoing issues concerning gene therapy is whether any or all of the four types of manipulation are ethically acceptable. At present, only somatic-cell gene therapy for the cure or prevention of serious disease is considered ethically appropriate, even by researchers like Anderson. In considering any application of gene therapy, basic respect for human dignity is, as always, the underlying moral principle. Like any other experimental medical treatment, gene therapy should be used to benefit the patient. Three case studies have been discussed at the end of this chapter.

Citation: Kreuzer H, Massey A. 2008. Analyzing Ethical Dilemmas in Gene Therapy, p 384-388. In Molecular Biology and Biotechnology: A Guide for Students, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817480_ch40

Key Concept Ranking

Gene therapy
0.51808757
Human Growth Hormone
0.50705886
Severe Combined Immunodeficiency
0.45876753
White Blood Cells
0.4010258
0.51808757
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 40.1
Figure 40.1

Gene replacement therapy. For genetic defects that affect cells derived from bone marrow stem cells, such as severe combined immunodeficiency disease, bone marrow is removed from the patient, and the stem cells are multiplied in cell culture. A correct copy of the gene is inserted into a viral vector, using recombinant DNA techniques. The virus is cultured with the bone marrow cells. It infects the cells and inserts the replacement gene into some of them. Radiation destroys the patient's defective bone marrow cells, and the physician injects cultured cells, now containing the correct gene, into empty bone marrow cavities. To date, only a few of the gene replacement trials have been therapeutic.

Citation: Kreuzer H, Massey A. 2008. Analyzing Ethical Dilemmas in Gene Therapy, p 384-388. In Molecular Biology and Biotechnology: A Guide for Students, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817480_ch40
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817480.chap40

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error